Literature DB >> 10433520

Activation of MAP kinases in growth responsive pancreatic cancer cells.

N Douziech1, E Calvo, J Lainé, J Morisset.   

Abstract

The implication of MAP kinases in the proliferation control of pancreatic cancer cells is still unknown. This study was undertaken to examine the contribution of the p44/p42 and p38 MAP kinases in the mitogenic response to epidermal growth factor (EGF) and bombesin in human pancreatic cancer cells, MIA PaCa-2 and PANC-1. Data indicate that EGF and bombesin stimulated growth of both cell lines. In MIA PaCa-2 cells, EGF and bombesin stimulated the in gel activation of p38 while p44/p42 kinases exhibited high basal activity and no response to stimuli. Growth and p38 activation were inhibited by genistein, wortmannin, PD98059 and SB203580, specific inhibitors of tyrosine kinase, phosphatidylinositol 3-kinase, MEK-1 and p38 kinases, respectively. In PANC-1 cells, EGF and bombesin stimulated p42 in gel activation; p44 remained highly activated and unresponsive to stimuli and p38 did not respond. Stimulated growth and p42 activation were inhibited by genistein, wortmannin and PD98059. Estimation of MAPK activities with a specific anti-active MAP kinase antibody indicated, however, that EGF increased the intensity of the bands corresponding to p42 and p44 MAP kinases in both cell lines, indicating that the mitogenic factor can regulate MAP kinase activity. Data also pointed out that ATP is sufficient to increase MAP kinase activity within the in gel assay technique and may thus explain the discrepancies existing between the in gel assay data and those obtained with the anti-active MAP kinase antibody.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433520     DOI: 10.1016/s0898-6568(99)00030-3

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  5 in total

1.  Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Takao Sugiyama; Shigenori Yamamoto; Makoto Sueishi; Takanobu Yoshida
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

2.  Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.

Authors:  Kenji Yokoi; Takamitsu Sasaki; Corazon D Bucana; Dominic Fan; Cheryl H Baker; Yasuhiko Kitadai; Toshio Kuwai; James L Abbruzzese; Isaiah J Fidler
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

3.  Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.

Authors:  Kenji Yokoi; Sun-Jin Kim; Premal Thaker; Sertac Yazici; Do-Hyun Nam; Junqin He; Takamitsu Sasaki; Paul J Chiao; Guido M Sclabas; James L Abbruzzese; Stanley R Hamilton; Isaiah J Fidler
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

Review 4.  Extracellular molecules involved in cancer cell invasion.

Authors:  Theodora Stivarou; Evangelia Patsavoudi
Journal:  Cancers (Basel)       Date:  2015-01-26       Impact factor: 6.639

Review 5.  The role of epidermal growth factor receptor in cancer metastasis and microenvironment.

Authors:  Takamitsu Sasaki; Kuniyasu Hiroki; Yuichi Yamashita
Journal:  Biomed Res Int       Date:  2013-08-07       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.